Phase 2 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a solid tumour (a non-blood cancer) that has spread to the brain, and whose doctor has recommended whole-brain radiation treatment
- People aged 18 or older
- People with a reasonably good level of physical functioning, as rated by their doctor using a standard scale (confirm with trial site)
- People who have previously had a targeted type of brain radiation called stereotactic radiosurgery, if their treating doctor considers this acceptable
- People who have previously had brain surgery (craniotomy), if their treating doctor considers this acceptable, and as long as at least 2 weeks have passed since that surgery before starting radiation treatment
- People who have previously had partial brain radiation, if the area treated was less than half of the brain and their treating doctor considers this acceptable
- People whose doctor expects them to survive longer than 6 months
- People who are willing and able to sign a written consent form
- People who are fluent in English and able to complete questionnaires and memory/thinking tests
- People who are able to have an MRI scan using a contrast dye called gadolinium
- People who are able to attend follow-up appointments for up to 2 years after radiation treatment ends
- People who are receiving, have received, or will receive other cancer treatments (such as chemotherapy or targeted therapy), at the discretion of their treating doctors
- Women who have not yet gone through menopause and have a negative pregnancy test
Who may not be able to join:
- People whose cancer has spread to the lining around the brain or spinal cord (a condition called leptomeningeal disease), as identified through clinical assessment, brain imaging, or spinal fluid testing
- People who have previously had whole-brain radiation treatment
- People who are currently taking, or have previously taken, a medication called memantine or any similar drug that works in the same way (NMDA antagonists)
- People who are known to be allergic to the contrast dye used in MRI scans, or who are unable to have an MRI scan for any reason
- People with serious uncontrolled health conditions that could affect their memory or thinking ability — for example, severe heart failure, unstable chest pain, a history of stroke, significant uncontrolled epilepsy, or mental health or personal circumstances that would make it difficult to follow the study requirements
- People who are pregnant, or who are not willing to use appropriate contraception during the period of radiation treatment
- People who are currently taking part in another clinical trial involving an investigational (not yet approved) systemic therapy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Helen A Shih, MD, MS, MPH, Massachusetts General Hospital
Phone: (617) 724-9627
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Patient Reported Quality of Life for NTS-WBRT (normal tissue sparing whole brain radiation therapy); Change in Patient Reported Symptom Burden for NTS-WBRT (normal tissue sparing whole brain radiation therapy)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.